C

THE REPORT OF

m

- 29. The method of treatment according to claim 27, wherein the acute or chronic inflammatory disease is a TNF-mediated disease.
- 30. The method of treatment according to claim 27, wherein said TNF binding protein comprises a sequence which is at least about 80% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 31. The method of treatment according to claim 27, wherein said TNF binding protein comprises a sequence which is at least about 90% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 32. The method of treatment according to claim 27, wherein said TNF binding protein comprises a sequence which is at least about 95% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 33. The method of treatment according to claim 27, wherein said TNF binding protein comprises a sequence which is at least about 99% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 34. The method of treatment according to claim 27, wherein said TNF binding protein comprises an amino acid having a sequence of SEQ ID NO: 2.
- 35. The method of treatment according to claim 27, wherein said TNF binding protein comprises a deletion variant of SEQ ID NO: 2 having an N-terminal or C-terminal deletion.
- 36. The method of theatment according to claim 27, wherein said TNF binding protein is non-glycosylated.
- 37. The method of treatment according to claim 27, wherein said TNF binding protein is glycosylated.
- The method of treatment according to claim 30, wherein an additional amino acid is added to the sequence of SEQ ID No. 2 and the additional amino acid is an N-terminal methionine having the residue number "0".
- 39. The method of treatment according to claim 27, wherein said TNF binding protein is produced by recombinant DNA methods.
- 40. The method of treatment according to claim 27, wherein said inflammatory disease is an inflammatory disease of a joint.
- 41. The method of treatment according to claim 27, wherein said inflammatory disease is rheumatoid arthritis.

Brank

- A dosage unit, comprising a COX2 inhibitor for the treatment of an acute or chronic 42. inflammatory disease in a patient and a TNF binding protein, wherein said dosage unit allows for administration of the COX2 inhibitor prior, concurrent, or after administration of the TNF binding protein.
 - 43. The dosage unit according to claim 42, wherein the COX2 inhibitor is celecoxib.
- 44. The dosage unit according to claim 42, wherein the acute or chronic inflammatory disease is a TNF-mediated disease.
- The dosage unit according to claim 42, wherein said TNF binding protein comprises a 45. sequence which is at least about 80% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 46. The dosage unit according to claim 42, wherein said TNF binding protein comprises a sequence which is at least about 90% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- The dosage unit according to claim 42, wherein said TNF binding protein comprises a 47. sequence which is at least about 95% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 48. The dosage unit according to claim 42, wherein said TNF binding protein comprises a sequence which is at least about 99% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 49. The dosage unit according to claim 42, wherein said TNF binding protein comprises an amino acid having a sequence of SEQ ID NO: 4.
- The dosage unit according to claim 42, wherein said TNF binding protein comprises a deletion 50. variant of SEQ ID NO: 2 having an N-terminal or C-terminal deletion.
 - The dosage unit according to claim 42, wherein said TNF binding protein is non-glycosylated. 51.
 - 52. The dosage unit according to claim 42, wherein said TNF binding protein is glycosylated.
- The dosage unit according to claim 45, wherein an additional amino acid is added to the 53. sequence of SEQ ID NO: 2 and the additional amino acid is an N-terminal methionine having the residue number "0".
- 54. The dosage unit according to claim 42, wherein said TNF binding protein is produced by recombinant DNA methods.
- The dosage unit according to claim 42, wherein said inflammatory disease is an inflammatory 55. disease of a joint.
- The dosage unit according to claim 42), wherein said inflammatory disease is rheumatoid 56. arthritis.

- 57. A pharmaceutical composition, comprising a TNF binding protein and a COX2 inhibitor for the treatment of an acute or chronic inflammatory disease in a patient.
- 58. The pharmaceutical composition according to claim 57 wherein the COX2 inhibitor is celecoxib.
- 59. The pharmaceutical composition according to claim 57, wherein the acute or chronic inflammatory disease is a TNF-mediated disease.
- 60. The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises a sequence which is at least about 80% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises a sequence which is at least about 90% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 62. The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises a sequence which is at least about 95% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 63. The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises a sequence which is at least about 99% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 64. The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises an amino acid having a sequence of SEQ ID NO: 2.
- 65. The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises an N-terminal or C-terminal deletion of SEQ ID NO: 2.
- 66. The pharmaceutical composition according to claim 57, wherein said TNF binding protein is non-glycosylated.
- 67. The pharmaceutical composition according to claim 57, wherein said TNF binding protein is glycosylated.
- 68. The pharmaceutical composition according to claim 60, wherein an additional amino acid is added to the sequence of SEQ ID NO: 2 and the additional amino acid is an N-terminal methionine having the residue number "0".
- 69. The pharmaceutical composition according to claim 57, wherein said TNF binding protein is produced by recombinant DNA methods.
- 70 The pharmaceutical composition according to claim 57, wherein said inflammatory disease is an inflammatory disease of a joint.



arthritis.

71.

The pharmaceutical composition to claim 57, wherein said inflammatory disease is rheumatoid